Impact of steatosis on perioperative outcome following hepatic resection

Kooby, David A.; Fong, Yuman; Suriawinata, Arief A.; Gönen, Mithat; Allen, Peter J.; Klimstra, David S.; DeMatteo, Ronald P.; D’Angelica, Michael I.; Blumgart, Leslie H.; Jarnagin, William R.

doi:10.1016/j.gassur.2003.09.012

Cited by 405 publications

(274 citation statements)

References 44 publications

Supporting

Mentioning

253

Contrasting

Unclassified

Order By: Relevance

“…These results indicate that perioperative chemotherapeutic regimens are far from being safe (Table 4). Moreover, the incidence of postoperative complications was In particular, liver disorders caused by irinotecanbased regimen (FOLFIRI) and oxaliplation-based regimen (FOLFOX) include fatty liver, steatohepatitis (yellow liver) (26)(27)(28), and sinusoidal dilation (blue liver) (29,30). Despite these findings, the results of the EORTC 40983 trial led to the recognition of "preoperative/ postoperative chemotherapy plus surgery" as a standard therapy for resectable liver metastases in Europe (31).…”

Section: Discussionmentioning

confidence: 99%

A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: Safety report of the UFT/LV study

Saiura¹,

Yamamoto²,

Hasegawa³

et al. 2014

DD&T

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: Safety report of the UFT/LV study

Saiura¹,

Yamamoto²,

Hasegawa³

et al. 2014

DD&T

View full text Add to dashboard Cite

“…Not only did they confirm their earlier findings that irinotecan was associated with a steatohepatitis, but they also found that patients with steatohepatitis had a significantly higher 90-day mortality (14.7%) compared to patients who did not have steatohepatitis (1.6%) (Vauthey et al, 2006). Others have investigated the effect of steatosis per se on clinical outcome following liver resection, finding that patients with steatosis had increased morbidity and were more likely to have had preoperative chemotherapy and had more postoperative complications compared to controls with no steatosis (Kooby et al, 2003). A further histological study of the resected liver specimens following oxaliplatin-based NC has revealed a distinct pattern of liver injury.…”

Section: Tablementioning

confidence: 99%

Safe liver resection following chemotherapy for colorectal metastases is a matter of timing

et al. 2007

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NC) can improve the resectability of hepatic colorectal metastases (CRM). However, there is concern regarding its impact on operative risk. We reviewed 750 consecutive liver resections performed for CRM in a single unit (1996 -2005) to evaluate whether NC affected morbidity and mortality. Redo hepatic resections or patients receiving adjuvant chemotherapy following primary resection were excluded. A total of 245 resections were performed in patients not requiring NC (control group) (mean age 63, 67% male) and 252 in patients who had NC (mean age 62, 67% male). The mean (s.d.) duration of surgery was less in the control group (241(64) vs 255(64)min, P ¼ 0.014) as was the mean blood loss (390(264) vs 449(424)ml, P ¼ 0.069). Postoperative mortality (2 vs 2%) and morbidity (27 vs 29%, P ¼ 0.34) was similar between groups. More NC patients developed septic (2.4%) or respiratory (10.3%) complications compared to controls (0 and 5.3%, Po0.03), with significantly more surgical complications if the interval between stopping NC and undergoing surgery was p4 weeks (11%), compared to 5 -8 (5.5%) or 9 -12 (2.6%) weeks (P ¼ 0.009). The data suggest that liver resection for CRM is safe following NC. Early hepatobiliary involvement in multidisciplinary cancer care may lead to avoidance of potential perioperative adverse events.

show abstract

“…This view is shared by others who examined hepatic regeneration following hepatectomy, and found that though alcoholic steatohepatitis and NAFLD shared similar hepatic histology, liver regeneration was not impaired in NAFLD (16) .…”

Section: Discussionmentioning

confidence: 72%

Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases

Pathak

Tang

Terlizzo

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS

show abstract

Impact of steatosis on perioperative outcome following hepatic resection

Cited by 405 publications

References 44 publications

A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: Safety report of the UFT/LV study

A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: Safety report of the UFT/LV study

Safe liver resection following chemotherapy for colorectal metastases is a matter of timing

Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases

Contact Info

Product

Resources

About